• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NIH Delays Basic Brain Research Rules

NIH Delays Basic Brain Research Rules

August 20, 2018
William Myers

NIH has delayed a controversial new policy that would have required basic brain and behavioral researchers to treat their work as clinical trials.

The measure, originally set to take effect next month, called for scientists who study human cognition or behavior — for example using brain scans with healthy volunteers — to follow the same rules as studies testing drugs or diagnostics, including registering their studies and publishing results in the ClinicalTrials.gov federal database.

NIH made the move in response to a 2016 Government Accountability Office (GAO) report that slammed the agency for failing to keep track of nearly $3 billion in taxpayer dollars it had allocated to support scientific research.

Psychologists and neurologists had pushed back against the policy, insisting it would subject them to extraneous government oversight of experiments that, in their view, didn’t involve any real risk to human subjects and made no sense for studies that weren’t testing a treatment.

They also balked about massive unnecessary paperwork and administrative nightmares they predicted the new requirements would create — and complained that some of NIH’s language about “priority” research could be misinterpreted and block funding for exploratory research and training.

NIH postponed the move a year — until Sept. 24, 2019 — after Congress asked it to delay action.

In the interim, behavioral researchers will still have to register their proposed studies “with the expectation that data will eventually be transported to ClinicalTrials.gov,” the NIH says. They’ll also have to take special training on clinical practices, regardless of the focus of their research.

NIH is the nation’s largest funder of clinical trials. After the GAO released its report, the agency acknowledged that it “had difficulty reporting how many clinical trials it has funded” and that “results from many NIH-funded clinical trials are never published or reported in a public database.”

The new policy was among steps it took designed to remedy the lapses and increase transparency of NIH-funded clinical trials.

Last year more than 3,500 scientists signed an online petition urging NIH Director Francis Collins to scrap the plan —and opponents had hoped NIH would scuttle it. But they said they’re pleased to have extra time to adjust and provide more input.

“APA supports policies that encourage open science approaches such as preregistration of studies and data sharing,” Howard Kurtzman, executive director of the American Psychological Association, which opposes the policy, told CenterWatch. “Such policies should be developed with the input of the research community and be sensitive to the purposes and nature of the research being conducted.”

The NIH said it plans to work with scientists to iron out wrinkles and ease compliance over the next year.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing